CoViD-19 Patient in Reims University Hospital in March to April 2020 (COVID-Reims)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04553575 |
Recruitment Status :
Recruiting
First Posted : September 17, 2020
Last Update Posted : October 5, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Medical context: Follow-up of a retrospective cohort of 499 cases of CoViD-19, hospitalized at the University Hospital of Reims during the health crisis, prospectively up to two years of follow-up.
Possible intervention for serological monitoring, leading to a change from category 3 to category 2 (French law on human person research)
Aim of the study: To know the factors of gravity of CoViD-19, to know its prognostic factors, to see how the evolution of the treatments implemented have influenced the fate of the patients.
Material and methods:
Type of study: cohort study Population: Patients in the CoViD-19 cohort - Reims Calendar: September 2020 - July 2022
Expected results: Better knowledge of the cares of patients with CoViD-19
Condition or disease | Intervention/treatment |
---|---|
Coronavirus Infections | Biological: serology |
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 499 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 2 Years |
Official Title: | Follow-up CoViD-19 Patients Hospitalized in Reims University Hospital Between the 01/03/2020 and 30/04/2020 |
Actual Study Start Date : | September 25, 2020 |
Estimated Primary Completion Date : | September 2022 |
Estimated Study Completion Date : | September 2022 |

Group/Cohort | Intervention/treatment |
---|---|
CoViD-19 patients cohort
Patients are followed for 2 years after diagnosis. The only one intervention is blood samples withdrawn for serologies
|
Biological: serology
biological blood samples withdrawn at 6, 12 and 24 months |
- Health status in the 2 years after CoViD-19 diagnosis [ Time Frame: 2 years follow up ]status : dead or alive persistante respiratory distress (yes / no)
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patient hospitalized for CoViD-19 infection during the health crisis, in a short-stay service of Reims University Hospital and included in Covid-19 Cohort
- Age > 18 years
- Patient who benefit from the national health insurance coverage
- patient agree for participation (consent form signed)
Exclusion Criteria:
- Patient protected by law

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04553575
Contact: Damien Jolly | 03 26 78 84 72 ext 0033 | djolly@chu-reims.fr |
France | |
Chu Reims | Recruiting |
Reims, France, 51092 | |
Contact: Damien JOLLY 326788472 ext 33 djolly@chu-reims.fr |
Responsible Party: | CHU de Reims |
ClinicalTrials.gov Identifier: | NCT04553575 |
Other Study ID Numbers: |
PO20124* |
First Posted: | September 17, 2020 Key Record Dates |
Last Update Posted: | October 5, 2020 |
Last Verified: | October 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Coronavirus Infections Severe Acute Respiratory Syndrome Coronaviridae Infections Nidovirales Infections |
RNA Virus Infections Virus Diseases Respiratory Tract Infections Respiratory Tract Diseases |